Xiamen Amoytop Biotech (SHA:688278) adjusted the proposed investment amounts for its convertible bond fundraising projects, following a net proceeds shortfall.
Net proceeds came to 1.52 billion yuan, lower than the planned 1.53 billion yuan, according to a Wednesday filing with the Shanghai bourse.
The adjustments affect the Biotech innovation integration center project, which saw its allocation reduced to 446.2 million yuan from 461.9 million yuan.
Shares of the drugmaker were up 7% Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.